scholarly journals Cerebellar Glioblastoma

2020 ◽  
Author(s):  
Keyword(s):  
Cerebellar Glioblastoma

Characteristics and management of hydrocephalus in adult patients with cerebellar glioblastoma: lessons from a French nationwide series of 118 cases

2021 ◽  
Author(s):  
Thiébaud Picart ◽  
Chloé Dumot ◽  
David Meyronet ◽  
Johan Pallud ◽  
Philippe Metellus ◽  
...  
Keyword(s):  
Adult Patients ◽  
Cerebellar Glioblastoma

Development of a cerebellar glioblastoma at the same location of a previously stable cavernous angioma

2021 ◽  
Author(s):  
Diogo Goulart Corrêa ◽  
Luis Alcides Quevedo Cañete ◽  
Luiz Celso Hygino da Cruz
Keyword(s):  
Cavernous Angioma ◽  
Cerebellar Glioblastoma

scholarly journals Discernable differences in the genetic and molecular profile of cerebellar glioblastoma

2019 ◽  
Vol 8 (Suppl 6) ◽  
pp. S553-S558 ◽  
Author(s):  
Muhibullah S. Tora ◽  
D. Cory Adamson
Keyword(s):  
Molecular Profile ◽  
Cerebellar Glioblastoma

scholarly journals BT-09 CLINICAL AND MOLECULAR GENETIC FEATURE OF CEREBELLAR GLIOBLASTOMA

2019 ◽  
Vol 1 (Supplement_2) ◽  
pp. ii37-ii38
Author(s):  
Shohei Iijima ◽  
Kuniaki Saito ◽  
Saki Shimizu ◽  
Keiichi Kobayashi ◽  
Daisuke Shimada ◽  
...  
Keyword(s):  
Clinical Course ◽  
Molecular Genetic ◽  
Progression Free Survival ◽  
Tumor Location ◽  
Cerebellar Hemisphere ◽  
Free Survival ◽  
Specific Pcr ◽  
Cerebellar Glioblastoma ◽  
Number Variation ◽  
Dependent Probe

Abstract INTRODUCTION Cerebellar glioblastoma (cGBM) is extremely rare, accounting for 0.7–0.9% of all gliomas. Few studies have reported on clinical course, histopathology, and prognosis. In this report, we discussed cases which were diagnosed as cGBM, and were treated in our institute. Materials and Methods We retrospectively analyzed 9 cGBMs (age ranged 41 to 85 years, median 69), operated at our institute after 2010 January, and evaluated their <MGMT> promoter methylation, <IDH1> mutation, and Copy Number Variation status detected by methylation-specific PCR (MSP), DNA sequencing or immunohistochemistry, and Multiplex Ligation-dependent Probe Amplification (MLPA), respectively. RESULTS All patients underwent resection; 3 gross total resections (GTRs, 33%), 2 subtotal resections, 4 partial resections, with relatively low achievement of GTR. The tumor location predominated in the cerebellar hemisphere (7 patients, 78%) over vermis (2). One patient had brain stem invasion. After surgery, 8 patients received temozolomide (TMZ) and radiotherapy (RT), while did only one RT alone. After recurrence, three patients were treated with bevacizumab monotherapy, and other three received either TMZ and RT, TMZ and ACNU, or TMZ monotherapy. The median progression-free survival (PFS) was 12.0 months, and the median overall survival (OS) was 17.1 months. Five patients (56%) were <MGMT> methylated, whereas all were <IDH1>wild-type. <PTEN> deletion was negative in all patients. <EGFR> amplification and combined <PDGFR> amplification and <CDKN2A> deletion were found in one patient each. DISCUSSION Despite the lower rate of GTR, there was a tendency of longer PFS compared to supratentorial GBM (sGBM). The clinical course after recurrence was unfavorable, and OS thereafter was similar to that of sGBM. cGBMs appeared to lack the typical genetic mutations occurred in sGBM, suggesting that cGBMs might be stimulated with different regulatory cellular signals.

scholarly journals Cerebellar glioblastoma multiforme in an adult

2006 ◽  
Vol 64 (1) ◽  
pp. 132-135 ◽  
Author(s):  
João Paulo Mattos ◽  
Horacio Armando Marenco ◽  
José Maria Campos ◽  
Andréa Vasconcellos Faria ◽  
Luciano Souza Queiroz ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Literature Review ◽  
Treatment Options ◽  
Rare Tumor ◽  
Imaging Studies ◽  
Brazilian Literature ◽  
The Third ◽  
Pathological Characteristics ◽  
Cerebellar Glioblastoma ◽  
High Degree

Cerebellar glioblastoma multiforme (GBM) is a rare tumor. This is the third case published in Brazilian literature and, the last one has been described more than 15 years ago. The aggressive behavior of GBM prompts for fast treatment, which can be hampered by the fact that the diagnosis of GBM requires a high degree of suspicion. We describe a case of GBM in a 46 years old man. In conjunction, we present a literature review including particular issues, clinical data, advances in imaging studies, pathological characteristics, treatment options and the behavior of such malignant tumor.

Glioblastoma Multiforme of the Cerebellum in an Elderly Man. A Case Report

1989 ◽  
Vol 75 (6) ◽  
pp. 626-629 ◽  
Author(s):  
Jeffry Rosenfeld ◽  
Marco Lorenzo Rossi ◽  
Michael Briggs
Keyword(s):  
Case Report ◽  
Glioblastoma Multiforme ◽  
Cerebellar Glioblastoma

Glioblastoma multiforme of the cerebellum is rare and comprises a small fraction of all glioblastomas. Eighty-five cases have been reported in the literature to date. A 75 year old man is reported with a left cerebellar glioblastoma multiforme. The pathogenesis, course, treatment and prognosis are reviewed.

H3K27M mutation in adult cerebellar glioblastoma

2020 ◽  
Vol 71 ◽  
pp. 316-317 ◽  
Author(s):  
Victor M. Lu ◽  
Oluwaseun O. Akinduro ◽  
David J. Daniels
Keyword(s):  
Cerebellar Glioblastoma ◽  
H3k27m Mutation

scholarly journals NTRK2 Fusion Driven Pediatric Glioblastoma: Identification of key molecular drivers by personalized oncology

2019 ◽  
Vol 46 (s2) ◽  
pp. S64
Author(s):  
Levine ◽  
Y Shen ◽  
K Mungall ◽  
J Serrano ◽  
M Snuderl ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Checkpoint Inhibitors ◽  
Braf V600e ◽  
Current Status ◽  
Driver Mutations ◽  
List Type ◽  
Idh1 R132h ◽  
Tyrosine Kinase 2 ◽  
Cerebellar Glioblastoma ◽  
Molecular Landscape

We describe the case of an 11-month-old girl with a rare cerebellar glioblastoma driven by a NACC2-NTRK2 (Nucleus Accumbens Associated Protein 2-Neurotrophic Receptor Tyrosine Kinase 2) fusion. Initial workup of our case demonstrated homozygous CDKN2A deletion, but immunohistochemistry for other driver mutations, including IDH1 R132H, BRAF V600E, and H3F3A K27M were negative, and ATRX was retained. Tissue was subsequently submitted for personalized oncogenomic analysis, including whole genome and whole transcriptome sequencing, which demonstrated an activating NTRK2 fusion, as well as high PD-L1 expression, which was subsequently confirmed by immunohistochemistry. Furthermore, H3 and IDH demonstrated wildtype status. These findings suggested the possibility of treatment with either NTRK- or immune checkpoint- inhibitors through active clinical trials. Ultimately, the family pursued standard treatment that involved Head Start III chemotherapy and proton radiotherapy. Notably, at most recent follow upapproximately two years from initial diagnosis, the patient is in disease remission and thriving, suggesting favorable biology despite histologic malignancy. This case illustrates the value of personalized oncogenomics, as the molecular profiling revealed two actionable changes that would not have been apparent through routine diagnostics. NTRK fusions are known oncogenic drivers in a range of cancer types, but this is the first report of a NACC2-NTRK2 fusion in a glioblastoma.LEARNING OBJECTIVESThis presentation will enable the learner to:1.Explore the current molecular landscape of pediatric high grade gliomas2.Recognize the value of personalized oncogenomic analysis, particularly in rare and/or aggressive tumors3.Discuss the current status of NTRK inhibitor clinical trials

Adult cerebellar glioblastoma cases have different characteristics from supratentorial glioblastoma

2011 ◽  
Vol 29 (2) ◽  
pp. 87-95 ◽  
Author(s):  
Satoshi Utsuki ◽  
Hidehiro Oka ◽  
Yoshiteru Miyajima ◽  
Chihiro Kijima ◽  
Yoshie Yasui ◽  
...  
Keyword(s):  
Cerebellar Glioblastoma ◽  
Different Characteristics
Sign in / Sign up

Export Citation Format

Share Document